优选由那格列奈速释层与盐酸二甲双胍缓释层组成的双层片处方。
摘要:目的评价那格列奈治疗2型糖尿病的有效性和安全性。
那格列奈与瑞格列奈治疗2型糖尿病的随机双盲对照研究
原位聚合那格列奈分子印迹手性固定相的分子识别特性研究
那格列奈联合甘精胰岛素治疗老年2型糖尿病的疗效及安全性
RP-HPLC手性流动相添加法分离测定那格列奈对映异构体
那格列奈治疗2型糖尿病的有效性和安全性的随机、双盲、对照研究
1·Considering the powerful effects of lifestyle interventions in other trials, this design feature may have reduced the magnitude of the potential benefit from nateglinide.
考虑到其它试验中生活方式干预的强大效应,本研究的设计可能已经减少了那格列奈潜在利益的幅度。
2·Finally, owing to its rapid-action profile, nateglinide has a relatively low risk of causing hypoglycemia.
最后,由于起效快,那格列奈造成低血糖风险相对较低。
3·To optimize the formula of the double-layer tablet of nateglinide rapid-release layer and metformin hydrochloride sustained-release layer.
优选由那格列奈速释层与盐酸二甲双胍缓释层组成的双层片处方。
4·OBJECTIVE To establish the dissolution method for nateglinide tablets.
目的:建立那格列奈片的体外溶出度的测定方法。
5·Nateglinide is a novel non-sulfonylurea antidiabetic agent by stimulating insulin secretion. Its action occurs rapidly and sustains shortly.
那格列奈是一种新型的非磺酰脲类促胰岛素分泌的降糖新药,其起效快且作用时间较短。